Deal Watch: NASH Space Heats Up With Tobira/Regado Reverse-Merger

Roche buys out French biotech Trophos, with plans to continue developing its failed ALS candidate in spinal muscular atrophy. Meanwhile, the ramifications from last year’s complex Novartis/GSK tie-up continue, as Novartis transfers a Phase III BRAF inhibitor to Array a month after returning a MEK inhibitor to its former partner.

“The Pink Sheet” regularly provides commentary and perspective on key business deals. Here’s a summary of the most noteworthy transactions taking place between Jan. 16-23.

More from Archive

More from Pink Sheet

Health Canada Proposes Major Regulatory Overhaul To Combat Drug, Device Shortages

 
• By 

Canada’s health products regulator is inviting feedback on a range of new and revised guidelines and regulatory tools that explain how drug and device companies will be able to comply with significant changes proposed to its shortages framework.

Ozempic & NAION: EU Safety Panel Continues Probe Into Link With Eye Condition

 

The European Medicines Agency says it will take appropriate measures to update the Ozempic’s package leaflet if new evidence arises.

New EU Filings

 

Doxecitine/doxribtimine, UCB’s investigational orphan drug for pediatric and adult patients with thymidine kinase 2 deficiency, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.